LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

To join this study, you generally need to be at least 18 years old (22 in the USA) and have non-small cell lung cancer that has spread to other parts of your body. Your cancer must have been recently diagnosed as advanced, meaning you haven't started treatment for it yet. If you had chemotherapy or radiotherapy for an earlier, non-spreading lung cancer more than a year ago, you might still be able to join.

Your general health also needs to be good enough for you to take part, which doctors call having a good 'performance status'. This means you should be able to carry out most of your daily activities without much difficulty. You'll also need certain blood test results to show key organs are working well.

There are also reasons you might not be able to join. For example, if your lung cancer has certain genetic changes for which specific targeted treatments are recommended, or if you have a mixed type of lung cancer. You also can't have had recent major surgery or certain types of radiotherapy too close to the start of the study.

If you decide to take part in the LUNAR-2 study, you will receive either the new combination treatment (TTFields device plus pembrolizumab and chemotherapy) or the standard treatment (pembrolizumab and chemotherapy alone). This decision is made randomly, like flipping a coin. You will have regular hospital visits for your chemotherapy and pembrolizumab infusions, and to have check-ups and scans to see how your treatment is working. The TTFields device would be worn for a significant part of each day, delivered through patches on your skin. The total duration of your participation will depend on how you respond to the treatment and your doctors' guidance, but it involves ongoing treatment and monitoring.